Who founded Rgenta Therapeutics?

Rgenta Therapeutics was founded by Travis Wager, Hualin Simon Xi, Zhiping Weng, Simon Xi in 2019.

Who are Rgenta Therapeutics's investors?

Rgenta Therapeutics's investors include Delos Capital, Vivo Capital, AMR Action Fund, Boehringer Ingelheim Venture Fund, Korea Investment Partners, Lilly Asia Ventures, Matrix Capital Management, Matrix Partners China.

How much funding has Rgenta Therapeutics raised?

Rgenta Therapeutics has disclosed $88.9M raised across 4 rounds.

Where is Rgenta Therapeutics headquartered?

Rgenta Therapeutics is headquartered in Cambridge, US.

Rgenta Therapeutics

Cambridge, US · Founded 2019 · Delaware corporation · 32 employees on LinkedIn · 14 known investors

Find your way into Rgenta Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Rgenta Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.

AI & Machine Learning Biotech Deep Tech Healthtech

Founders & leadership

Rgenta Therapeutics was founded in 2019 by Travis Wager, Hualin Simon Xi, Zhiping Weng, and Simon Xi.

Travis Wager Co-Founder, President and CSOHe brings 25 years of leadership experience in neuroscience, rare disease, and oncology research and drug discovery, with expertise in brain-penetrant small molecule design.

Hualin Simon XiCo-founder

Zhiping Weng Co-Founder and Scientific AdvisorDr. Zhiping Weng holds the Li Weibo Chair in Biomedical Research at the University of Massachusetts Medical School and directs its Program in Bioinformatics and Integrative Biology. She co-founded Rgenta Therapeutics in 2018 alongside Travis Wager and Simon Hualin Xi, and her research focuses on genomics, epigenomics, and transcriptomics using computational methods to study gene regulation and protein interactions.

Simon Xi Co-founder and CEOSimon Xi has over 20 years of experience in pharmaceutical drug discovery, with expertise in CNS, rare diseases, and oncology, and has led research programs at major pharmaceutical companies. He is co-founder and CEO of Rgenta Therapeutics, which develops orally available small molecule therapies targeting RNA for oncology and neurological disorders, and serves as a principal investigator on NIH-funded genomics consortia and adjunct faculty at Brandeis University.

Jackie WallingCMO

Debasish RoychowdhuryNamed on SEC filing

Sun LinghaoNamed on SEC filing

Board

Judith LiBoard director

Hongbo Lu Board directorManaging Partner at Lilly Asia Ventures

Martin Heidecker Member Board of Directors Rgenta Therapeutics Inc.2020–2021CIO at AMR Action Fund

Investors · 14

Delos Capitallisted by Delos CapitalCambridge

How we know: funding news · deloscapital.com · Not right? Tell us

Vivo Capitallisted by Vivo CapitalPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · a partner's Signal profile · funding news · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us

AMR Action FundreportedBostonvia Martin Heidecker · board

How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

Boehringer Ingelheim Venture FundreportedIngelheim am Rhein · $16.2M

How we know: deloscapital.com · Not right? Tell us

Korea Investment PartnersreportedSeoul · $3M – $10M

How we know: funding news · open dataset · 5k.vc investor directory · Not right? Tell us

Lilly Asia VenturesinferredHong Kongvia Hongbo Lu · board

How we know: board seat on SEC Form D · Not right? Tell us

Matrix Capital ManagementreportedPortsmouth

How we know: globalgenes.org · Not right? Tell us

Matrix Partners ChinareportedBeijing

How we know: deloscapital.com · Not right? Tell us

Also in the syndicate · 6

AZ-CICC Healthcare Investment FundleadBIVFleadKaitaiKorean Investment PartnersLilly Asia VentureMatrix Capitalslead

Funding

SEC filings, press & company announcements

$88.9M disclosed across 4 rounds · 2020–2022

$52MSeries ANov 2022 · 3 sources
AZ-CICC Healthcare Investment Fund (lead), Boehringer Ingelheim Venture Fund, Delos Capital, Korean Investment Partners, Lilly Asia Venture, Matrix Partners China, Vivo Capital
Source ↗
$18Mseed extension roundMay 2021 · 2 sources
BIVF (lead), Matrix Capital (lead), Matrix Capitals (lead), Kaitai, Lilly Asia Venture, Vivo Capital
Source ↗

▶$8.9MraisedFeb 2022 · 6 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Judith LiDirector
Sun LinghaoDirector
Hualin Simon XiExecutive Officer, Director
Fei ShenDirector
Debasish RoychowdhuryDirector
Hongbo LuDirector
Travis WagerExecutive Officer
Zhiping WengDirector

Offering amount: $8.9M
Amount sold: $8.9M
First sale: Nov 2021
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedMar 2021 · 6 investors · Other

Rule 506(b)

Officers, directors & promoters on the filing

Judith LiDirector
Hongbo LuDirector
Debasish RoychowdhuryDirector
Travis WagerExecutive Officer
Sun LinghaoDirector
Hualin Simon XiExecutive Officer, Director
Zhiping WengDirector
Martin HeideckerDirector

Offering amount: $38M
Amount sold: $10M
First sale: Jan 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 7

OrnaOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.

RonatherapeuticsRona Therapeutics develops siRNA-based therapeutics using its GAIA platform to target metabolic and cardiovascular conditions including hypertriglyceridemia, obesity, ASCVD, and MASH. Its pipeline includes APOC3, INHBE, PCSK9-Lp(a), and angiotensinogen-targeting candidates for patients with cardiovascular and metabolic diseases.

Regeneron NASDAQ: REGN www.regeneron.comRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

OrogentxOrogen Therapeutics uses AI and machine learning to accelerate drug discovery, focusing on small molecule candidates for immuno-inflammatory diseases. The company combines computational chemistry, DNA-encoded library technology, and medicinal expertise to develop novel therapeutic medicines.

Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.

RedonaRedona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology. The company is led by experienced biotech executives with backgrounds in immunology, oncology, and translational medicine.

Companies working in the same space as Rgenta Therapeutics.

In the news

Rgenta Therapeutics Announces the Successful Completion of Extension of Seed Financingprnewswire.com · May 2021

Frequently asked questions

What does Rgenta Therapeutics do?: Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease. It operates in the RNA-targeted drug development space.
Who founded Rgenta Therapeutics?: Rgenta Therapeutics was founded by Travis Wager, Hualin Simon Xi, Zhiping Weng, Simon Xi in 2019.
Who are Rgenta Therapeutics's investors?: Rgenta Therapeutics's investors include Delos Capital, Vivo Capital, AMR Action Fund, Boehringer Ingelheim Venture Fund, Korea Investment Partners, Lilly Asia Ventures, Matrix Capital Management, Matrix Partners China.
How much funding has Rgenta Therapeutics raised?: Rgenta Therapeutics has disclosed $88.9M raised across 4 rounds.
Where is Rgenta Therapeutics headquartered?: Rgenta Therapeutics is headquartered in Cambridge, US.